Effectiveness and safety of solifenacin succinate in treatment of overactive bladder

Abstract

Overactive bladder is a group of syndromes characterized by symptoms of urinary urgency, seriously affecting the quality of life of patients.Solifenacin succinate is a new generation of muscarinic acetylcholine receptor(M receptor) antagonist with high selectivity for detrusor, and it can not only obviously relieve the symptoms of urgency and incontinence, increase urination and reduce micturition frequency, but also improve lower urinary tract symptoms for patients after implantation of ureteral stents. The main adverse reactions of M receptor antagonist are dry mouth, cognitive impairment and urinary retention.Compared with oxybutynin and tolterodine, the incidences of dry mouth and urinary retention caused by solifenacin succinate are low, and it also has less effect on cognitive function.But for the patient with high risk factors(such as combined use of other anticholinergic drugs and changes of blood brain barrier caused by primary diseases)and elderly patients with a history of cognitive impairment can induce or worsen the risk of cognitive impairment. During the first month of taking solifenacin succinate, more attention should be paid on the changes of residual urine volume in order to reduce the risk of acute urinary retention. Key words: Urinary bladder, overactive; Muscarinic antagonists; Solifenacin succinate